Zimmer Biomet Holdings, Inc. (ZBH)
| Market Cap | 19.12B -10.4% |
| Revenue (ttm) | 8.51B +8.6% |
| Net Income | 806.70M -2.0% |
| EPS | 4.12 +0.2% |
| Shares Out | 190.74M |
| PE Ratio | 24.35 |
| Forward PE | 11.44 |
| Dividend | $0.96 (0.96%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 1,272,263 |
| Open | 100.14 |
| Previous Close | 100.98 |
| Day's Range | 99.28 - 100.87 |
| 52-Week Range | 79.12 - 108.29 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 107.57 (+7.31%) |
| Earnings Date | Aug 5, 2026 |
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price target is $107.57, which is an increase of 7.31% from the latest price.
News
Zimmer Biomet price target raised to $100 from $83 at Canaccord
Canaccord analyst Caitlin Cronin raised the firm’s price target on Zimmer Biomet (ZBH) to $100 from $83 and keeps a Hold rating on the shares. The firm updated its model…
Zimmer Biomet price target raised to $106 from $92 at Truist
Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold rating on the shares. Zimmer Biomet delivered a Q2 organic revenue beat…
Zimmer Biomet price target raised to $106 from $92 at Truist
Truist raised the firm’s price target on Zimmer Biomet (ZBH) to $106 from $92 and keeps a Hold rating on the shares. The firm notes the company delivered a Q2…
Zimmer Biomet price target raised to $104 from $92 at Baird
Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $104 from $92 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.
Zimmer Biomet price target raised to $98 from $88 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Zimmer Biomet (ZBH) to $98 from $88 and keeps a Hold rating on the shares.
Zimmer Biomet price target raised to $120 from $115 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Zimmer Biomet (ZBH) to $120 from $115 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $110 from $105 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $105 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $93 from $91 at Bernstein
Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $93 from $91 and keeps a Market Perform rating on the shares following quarterly results. It was a solid…
Zimmer Biomet price target raised to $96 from $95 at BMO Capital
BMO Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $96 from $95 and keeps a Market Perform rating on the shares.
Zimmer Biomet price target raised to $110 from $101 at RBC Capital
RBC Capital analyst Kendall Au raised the firm’s price target on Zimmer Biomet (ZBH) to $110 from $101 and keeps an Outperform rating on the shares.
Zimmer Biomet price target raised to $99 from $93 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Zimmer Biomet (ZBH) to $99 from $93 and keeps a Neutral rating on the shares.
Zimmer Biomet Holdings Earnings Call Transcript: Q2 2026
Q2 sales grew 4.8% reported and 4% organically, led by strong U.S. hip and technology growth. Guidance for full-year organic revenue and adjusted EPS was raised, with robust cash flow and continued investments in innovation, Salesforce transformation, and M&A.
Zimmer Biomet Holdings Earnings release: Q2 2026
Zimmer Biomet Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q2 2026
Zimmer Biomet Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per sh...
Zimmer Biomet upgraded to Buy from Sell at UBS
UBS analyst Patrick Wood upgraded Zimmer Biomet (ZBH) to Buy from Sell with a price target of $115, up from $89, after assuming coverage of the name. Zimmer Biomet is…
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
WARSAW, Ind., July 14, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the com...
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
WARSAW, Ind., July 13, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be we...
BMO starts Zimmer at Market Perform, says valuation appears attractive
BMO Capital analyst Vik Chopra initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target Valuation appears attractive, but the firm would like to see…
Zimmer Biomet initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target
Zimmer Biomet price target lowered to $110 from $120 at Evercore ISI
Evercore ISI lowered the firm’s price target on Zimmer Biomet (ZBH) to $110 from $120 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life…
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expa...
Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront
Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a FDA-cleared, drug-free medical device that relieves pain via cryoneurolysis-a process w...
Zimmer Biomet Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A major U.S. sales channel overhaul is underway, aiming for full transition by end-2027 and improved productivity. Recent product launches and acquisitions are driving growth, while innovation and robotics remain key priorities. Financially, 2026 is a transition year, with mid-single-digit growth targeted beyond.
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...